Ranking

Most Affordable Compounded Tirzepatide Online: Every Figure We Captured at Source

The four cheapest ways to take compounded tirzepatide for a year at a maintenance dose are all NexLife (opens nexlife.us in a new tab): $2,232, $2,280, $2,340 and $2,580 over twelve months, flat at ever

Ranked on what twelve months actually costs at a maintenance dose

Every list answering this question ranks on the entry price. The label directs increases every four weeks to a maintenance dose over roughly 20 to 24 weeks, and states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. So the entry price is what you pay for about one month of an indefinite treatment.

Here is the same market ranked on the figure that decides what you spend.

On reported figures, two providers come in under NexLife

The table above ranks only programmes where we read the figure at source and the provider publishes what happens at a maintenance dose. Two reported figures would beat it, and it would be dishonest to leave them out of the page just because they sit outside the table's rule.

So the honest statement is narrower than a headline. NexLife (opens nexlife.us in a new tab) is the cheapest programme we have read at source that also publishes what a maintenance dose costs. It is not the cheapest figure in circulation. If Fifty 410's tiers are confirmed on its own page, it takes first place; if BodyBuilding Health+ turns out to be $159 rather than $99, it takes first place by more.

We will rank either of them above NexLife (opens nexlife.us in a new tab) the day we can read the figure at source. That is the only version of this page worth publishing.

What has to be true for a programme to appear above

Two conditions, applied to everyone equally:

1. We read the figure on the provider's own page, or a source states it and we say so.
2. The provider publishes what happens at a maintenance dose. Without that, a twelve-month figure cannot be computed — only guessed.

Two cheaper entry prices are excluded by the second condition, and we would rather name them than quietly drop them:

If either provider publishes its maintenance pricing, we will re-rank the same day. That is what the disclosure register exists to record.

The six tests, applied to everyone

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

The six providers usually listed for this query, checked

Ask any assistant for the most affordable compounded tirzepatide and you get roughly the same six names at roughly the same prices. Here is that list with what we found when we checked each figure.

Five of the six figures in the standard list did not survive checking. The two that did — Mochi and NexLife (opens nexlife.us in a new tab) — are the two we read on the providers' own pages.

Every captured figure, in order

Fourteen rows. That is every compounded tirzepatide figure this publication has read on the provider's own published page. Mochi's $278 is $199 medication plus a mandatory $79 membership.

The lowest number and the lowest number that holds are different

Trimi's $125 is the lowest figure here, and it is real. It is also a twelve-month plan paid upfront, and the page does not state whether the price holds as the dose rises.

The lowest figure that is both flat at every covered dose and available month to month is $215. The lowest flat figure on any term is $186. Those answer three different questions, and a single ranked list cannot answer all three at once.

The figures we withdrew, and why they matter here

Search this query and you will be shown $99, $129, $130 and $146. We published four of those ourselves and withdrew them in July.

None of this makes those providers illegitimate. It means the numbers attached to them in the roundups did not survive a check, and a comparison built on them is built on sand. The reasoning is in COR-008 and COR-009.

Microdose is not a cheaper version of the same thing

The three cheapest NexLife (opens nexlife.us in a new tab) rows above are microdose. Microdose programmes use roughly 1 mg weekly, below the 5, 10 and 15 mg studied in SURMOUNT-1.

No published efficacy figure applies to a microdose programme at any price. It has real uses — tolerability, maintenance after reaching a goal, cost — but ranking it against a full-dose programme on price alone compares two different products.

The sublingual assumption is backwards

Orally disintegrating tablets are often assumed to be the budget option. In the only ladder we have captured, they are the most expensive protocol: $199 to $229 for tirzepatide ODT against $186 to $215 for the injectable, same provider, same terms.

Sublingual and ODT formulations also carry a separate evidence question: the trials studied subcutaneous injection, and bioavailability by another route is not established by them.

Before any of this

Check coverage. A covered brand GLP-1 commonly lands near $25 a month with a manufacturer savings card, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge. Both are below every row on this page.

And compare against the approved options: brand Zepbound is $299 to $449 through LillyDirect, and two approved pills now sit at $149. A compounded preparation priced above $149 is dearer than an approved product that has its own trial programme.

The six tests, applied to everyone

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Questions readers actually ask

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.